Clinical trials: HER2+ Breast Cancer
Breast Cancer Stage IV
Simvastatin Plus Dual Anti-HER2 Therapy for Metastatic Breast Cancer
This study recruits patients with metastatic breast cancer who have progressed on their current regimen of dual anti-HER2 therapy.
- Trial name
- SIMPHONY (NCT03324425)
- Testing
- Simvastatin 80mg
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- Baylor Breast Care Center
HER2 + Breast Cancer
A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer
The study is being conducted to evaluate the clinical efficacy of HLX22 in combination with HLX87 as first-line treatment in patients with HER2-positive recurrent or metastatic breast cancer
- Trial name
- NCT07294508
- Testing
- HLX87 + HLX22, HLX87 + Pertuzumab, T-Dxd + Pertuzumab
- Where
- China
- Volunteers
- 706 people
- Sponsor
- Shanghai Henlius Biotech
Breast Cancer; HER2-positive; Metastatic
Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)
The study will evaluate the efficacy and safety of trastuzumab deruxtecan (also known as T-DXd, DS-8201a), either alone or in combination with pertuzumab, in treating patients with Human epidermal growth factor receptor 2…
- Trial name
- NCT04784715
- Testing
- Trastuzumab deruxtecan, Taxane, Pertuzumab
- Where
- 283 sites in United States, Argentina and 25 more
- Volunteers
- 1,157 people
- Sponsor
- AstraZeneca
Locally Advanced or Metastatic Breast Cancer
A Study of Entinostat in Combination With Fulvestrant for the Treatment of Locally Advanced or Metastatic Breast Cancer
This study aims to evaluate the efficacy of Entinostat combined with Fulvestrant in HR+/HER2- advanced breast cancer patients with recurrence/progression after endocrine therapy (primary endpoint: progression-free survival…
- Trial name
- NCT07235618
- Testing
- Entinostat, Fulvestrant
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Sun Yat-sen University
Breast Cancer
Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women
The purpose of the study was to determine whether treatment with a PI3K inhibitor plus letrozole led to an increase in pathologic clinical response and Objective Response Rate compared to treatment with placebo plus letrozole in…
- Trial name
- NCT01923168
- Testing
- alpelisib, buparlisib
- Where
- 86 sites in United States, Australia and 15 more
- Volunteers
- 340 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer, Locally Advanced or Metastatic Solid Tumor
A Study of BL-M07D1 in Patients With Locally Advanced or Metastatic HER2-Positive/Negative Breast Cancer and Other Solid Tumors
In phase Ia study, the safety and tolerability of BL-B07D1 in patients with locally advanced or metastatic HER2-positive/low-expression breast cancer and other solid tumors will be investigated to determine the dose-limiting…
- Trial name
- NCT05461768
- Testing
- BL-M07D1
- Where
- 7 sites in China
- Volunteers
- 348 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Neoplasms, Breast
Study Of Lapatinib In Patients With Relapsed Or Refractory Inflammatory Breast Cancer
This study was designed to determine how effective and safe a new investigational drug, lapatinib, is in treating patients with treatment refractory or relapsed inflammatory breast cancer.
- Trial name
- NCT00105950
- Testing
- lapatinib
- Where
- 27 sites in United States, Belgium and 6 more
- Volunteers
- 126 people
- Sponsor
- GlaxoSmithKline
Advanced Solid Tumors, Metastatic Breast Cancer
Dose Finding Study of RAD001 (Everolimus, Afinitor®) in Combination With BEZ235 in Patients With Advanced Solid Tumors
Study has two parts: 1. Dose-finding: to determine the maximum tolerated dose (MTD) and to evaluate the safety and tolerability of RAD001 (everolimus , Afinitor®) in combination with BEZ235 in patients with advanced solid tumors.
- Conditions
- Advanced Solid Tumors, Metastatic Breast Cancer, Metastatic Renal Cell Carcinoma
- Trial name
- NCT01482156
- Testing
- RAD001 + BEZ235
- Where
- 10 sites in United States, Belgium and 5 more
- Volunteers
- 46 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer
Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients
This will be a multi-center, prospective, randomized, single-blinded, placebo-controlled phase II trial of trastuzumab + nelipepimut-S/GM-CSF versus trastuzumab + GM-CSF alone.
- Trial name
- HER3+ (NCT02297698)
- Testing
- NeuVax vaccine, Trastuzumab, GM-CSF
- Where
- 24 sites in United States
- Volunteers
- 100 people
- Sponsor
- Cancer Insight, LLC
HER2-negative Breast Cancer
A Study to Investigate the Biological Effects of AZD9833 in Women With ER-positive, HER2 Negative Primary Breast Cancer
This is a randomised, open-label, parallel-group, pre-surgical study aimed to investigate the biological effects, safety, tolerability, and pharmacokinetics (PK) of different doses of oral AZD9833 in post-menopausal women with…
- Trial name
- SERENA-3 (NCT04588298)
- Testing
- AZD9833
- Where
- 12 sites in Georgia, Mexico and 1 more
- Volunteers
- 135 people
- Sponsor
- AstraZeneca
Breast Cancer, Advanced Breast Cancer
Trastuzumab Deruxtecan and Lovastatin in HER2-low and Ultralow Advanced or Metastatic Breast Cancer
The purpose of this study is to evaluate the use of lovastatin, a cholesterol-depleting pro-drug that may lower CAV-1 levels, in order to increase HER2 expression on the cell surface of cancer cells and enhance the uptake and…
- Conditions
- Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer
- Trial name
- NCT07619365
- Testing
- Trastuzumab deruxtecan, Lovastatin
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Washington University School of Medicine
Breast Cancer
Trial of RAD001 in Triple Negative Metastatic Breast Cancer
The hypothesis of this clinical research study is to discover if the study drug RAD001 can shrink or slow the growth of Estrogen Receptor/Progesterone Receptor (ER/PR) negative or Human Epidermal growth factor Receptor 2 (Her2…
- Trial name
- NCT00827567
- Testing
- RAD 001
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Milton S. Hershey Medical Center
Early Breast Cancer
A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer
A phase III, multicenter, randomized, open-label trial to evaluate the efficacy and safety of ribociclib with Endocrine Therapy (ET) as an adjuvant treatment in women and men with Hormone Receptor positive (HR+), Human Epidermal…
- Trial name
- NATALEE (NCT03701334)
- Testing
- Ribociclib, Endocrine Therapy (ET)
- Where
- 387 sites in United States, Argentina and 18 more
- Volunteers
- 5,101 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer With Low to Intermediate HER2 Expression, Breast Cancer (Triple Negative Breast Cancer (TNBC))
Use of Magtrace Bracketing for Excision of Lesion and Sentinel Lymph Node Localization in Breast Conserving Surgery for Breast Cancer
Breast cancer is the commonest cancer affecting women worldwide. Early breast cancer is treated surgically with wide local excision of tumor with axillary staging operations like sentinel node biopsy.
- Conditions
- Breast Cancer With Low to Intermediate HER2 Expression, Breast Cancer (Triple Negative Breast Cancer (TNBC)), Breast Cancer (Triple Negative Type), Breast Cancer - Infiltrating Ductal Carcinoma
- Trial name
- MagBracket (NCT07844473)
- Testing
- Super paramagnetic iron oxide bracketing injection
- Where
- Saudi Arabia
- Volunteers
- 35 people
- Sponsor
- King Faisal Specialist Hospital & Research Center
Breast Cancer, Estrogen Receptor-positive Breast Cancer
Letrozole and Metronomic Capecitabine in ER-positive HER2 Negative Advanced Breast Cancer (B-001 Study)
A phase II clinical trial designed to test the effect of combining endocrinal therapy (Letrozole) with chemotherapy (Capecitabine) in first line treatment of advanced cases of female breast cancer with ER positive disease.
- Conditions
- Breast Cancer, Estrogen Receptor-positive Breast Cancer, Metastatic Breast Cancer
- Trial name
- B-001 (NCT04571437)
- Testing
- Capecitabine, Letrozole 2.5mg
- Where
- Egypt
- Volunteers
- 204 people
- Sponsor
- Cairo University
Metastatic Breast Cancer (MBC)
Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Metastatic Breast Cancer
This multicenter, randomized, open, parallel positive control study compares the clinical efficacy and safety of paclitaxel polymeric micelles for injection with TPC in HER2- MBC subjects who have failed ≥2 to≤4 previous…
- Trial name
- NCT06143553
- Testing
- Paclitaxel Polymeric Micelles for Injection, Eribulin Mesilate injection, Capecitabine Tablets
- Where
- 3 sites in China
- Volunteers
- 168 people
- Sponsor
- Shanghai Yizhong Pharmaceutical Co., Ltd.
Breast Cancer
Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer
The objective of this phase-III trial is to compare the efficacy and safety of sorafenib in combination with capecitabine versus capecitabine in combination with placebo in the treatment of subjects with locally advanced or…
- Trial name
- NCT01234337
- Testing
- Sorafenib (Nexavar, BAY43-9006), Capecitabine
- Where
- 153 sites in United States, Argentina and 21 more
- Volunteers
- 537 people
- Sponsor
- Bayer
HER2-positive Breast Cancer, Male Breast Cancer
Vaccine Therapy in Treating Patients With Stage IV Breast Cancer
This phase I/II trial is studying the side effects of escalating doses of adoptive T cell therapy in treating patients with stage IV breast cancer.
- Conditions
- HER2-positive Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
- Trial name
- NCT00791037
- Testing
- HER-2/neu peptide vaccine, leukapheresis, ex vivo-expanded HER2-specific T cells
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of Washington
Advanced Breast Cancer
Dalpiciclib Plus Letrozole and Capecitabine
to assess the effect of dalpiciclib plus letrozole and capecitabine of first-line treatment with breast cancer
- Trial name
- NCT05469750
- Testing
- Dalpiciclib+ letrozole +capecitabine
- Volunteers
- 48 people
- Sponsor
- Fujian Medical University Union Hospital
Advanced Solid Tumor, Advanced Breast Cancer
IMM2902, a HER2/SIRPα Bispecific MAb-Trap Antibody-receptor Fusion Protein, in Patients with HER2-expressing Advanced Solid Tumors
This trial is a first-in-human, open label, multi-center, dose escalation phase 1a study followed by a disease-specific dose expansion phase 1b study to evaluate the safety, efficacy, and pharmacokinetics (PK) of IMM2902, a…
- Conditions
- Advanced Solid Tumor, Advanced Breast Cancer, Advanced Gastric Cancer
- Trial name
- NCT05076591
- Testing
- IMM2902
- Where
- 3 sites in United States
- Volunteers
- 135 people
- Sponsor
- ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.